Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Company Overview

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$23.33 to C$23.33
• 52-Week Range: N/A
• Volume: 60,423 shs
• Average Volume: 166,586 shs
• Market Capitalization: C$2.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRIL Stock Analysis - Frequently Asked Questions

How do I buy shares of Trillium Therapeutics?

Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), Toronto-Dominion Bank (TD), Meta Platforms (META), Moderna (MRNA), Shopify (SHOP), Tesla (TSLA) and Bank of Nova Scotia (BNS).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:TRIL
• Previous Symbol: TSE:SSS
• CUSIP: N/A
• CIK: N/A
• Web: www.trilliumtherapeutics.com
• Phone: +1-416-5950627
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 12.04
• Quick Ratio: 11.54

Sales & Book Value

• Annual Sales: C$43,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.77
• Book Value: C$2.17 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 104,995,000
• Free Float: N/A
• Market Cap: C$2.45 billion
• Optionable: Not Optionable
• Beta: N/A